AbbVie Invests US$1.4bn to Build Future Workforce
AbbVie has announced a US$1.4bn investment to develop a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina.
The site will integrate advanced manufacturing, cutting-edge laboratory capabilities and AI-enabled operations to support next-generation production of immunology, neuroscience and oncology medicines.
AbbVie expects the campus to create 734 high-skilled roles – including engineers, scientists, manufacturing operators and laboratory technicians – signalling significant regional talent demand and new imperatives for workforce planning, skills development and AI-readiness.
Robert A. Michael, Chairman and CEO of AbbVie, adds: “By establishing this campus, we are strengthening our ability to support future medical breakthroughs while also creating new jobs and a long-term partnership with Durham and the State of North Carolina.”
This marks the company's first major investment in North Carolina, with the site selected for its proximity to Research Triangle Park, the strength of the region’s workforce and the capacity to support future expansion.
The move follows a broader wave of advanced manufacturing investment in the state, including Siemens’s new train manufacturing and rail services facility in Lexington and Toyota’s battery manufacturing facility, which held its opening ceremony in 2025. “We welcome AbbVie’s major investment in North Carolina,” said Governor Josh Stein.
For HR leaders, the decision signals intensified competition for specialised biopharma and advanced manufacturing talent across the Triangle.
It will require proactive workforce planning, university and training partnerships, reskilling programmes for sterile manufacturing and digital lab operations, and a strong employer value proposition to attract and retain high-demand STEM talent while building durable community and government partnerships.
Governor Josh Stein framed the state’s value proposition succinctly: “When you combine our world-renowned research and innovation with a strong, thriving life sciences hub, North Carolina quickly becomes the premier location for biopharmaceutical companies to do business.”
AbbVie’s move forms part of the company’s US$100bn commitment to US R&D and capital investments, including manufacturing, over the next decade.
The company currently employs approximately 29,000 people in the United States, with more than 6,000 working across its manufacturing campuses – signalling the scale at which it intends to build and sustain advanced production capabilities.
At the North Carolina site, AbbVie plans to deploy AI alongside advanced manufacturing and laboratory technologies to support production of immunology, neuroscience and oncology medicines.
The strategy aligns with market dynamics: McKinsey estimates biopharma is growing at roughly 6% annually, and a 2025 report indicates current production capacity is struggling to keep pace.
Given that biopharmaceutical manufacturing is sophisticated, highly variable and interdependent across end-to-end processes, McKinsey notes AI and advanced analytics could be a “shot in the arm” to optimise existing resources and enhance throughput for large molecules.
For senior HR leaders, the implications are immediate: building AI-enabled bioprocessing skills at scale, deepening GMP and quality expertise, and accelerating talent pipelines in data, automation and digital lab operations.
Success will hinge on strategic partnerships with universities and training providers in the Research Triangle, robust reskilling and change-management programs, and an employee value proposition that integrates wellbeing with a culture of safety, compliance and continuous improvement.
